149 related articles for article (PubMed ID: 28423360)
1. TIAM1 variants improve clinical outcome in neuroblastoma.
Sanmartín E; Yáñez Y; Fornés-Ferrer V; Zugaza JL; Cañete A; Castel V; Font de Mora J
Oncotarget; 2017 Jul; 8(28):45286-45297. PubMed ID: 28423360
[TBL] [Abstract][Full Text] [Related]
2. ARID1B alterations identify aggressive tumors in neuroblastoma.
Lee SH; Kim JS; Zheng S; Huse JT; Bae JS; Lee JW; Yoo KH; Koo HH; Kyung S; Park WY; Sung KW
Oncotarget; 2017 Jul; 8(28):45943-45950. PubMed ID: 28521285
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
[TBL] [Abstract][Full Text] [Related]
4. Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.
Bellini A; Bernard V; Leroy Q; Rio Frio T; Pierron G; Combaret V; Lapouble E; Clement N; Rubie H; Thebaud E; Chastagner P; Defachelles AS; Bergeron C; Buchbinder N; Taque S; Auvrignon A; Valteau-Couanet D; Michon J; Janoueix-Lerosey I; Delattre O; Schleiermacher G
Clin Cancer Res; 2015 Nov; 21(21):4913-21. PubMed ID: 26059187
[TBL] [Abstract][Full Text] [Related]
5. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.
Molenaar JJ; Koster J; Zwijnenburg DA; van Sluis P; Valentijn LJ; van der Ploeg I; Hamdi M; van Nes J; Westerman BA; van Arkel J; Ebus ME; Haneveld F; Lakeman A; Schild L; Molenaar P; Stroeken P; van Noesel MM; Ora I; Santo EE; Caron HN; Westerhout EM; Versteeg R
Nature; 2012 Feb; 483(7391):589-93. PubMed ID: 22367537
[TBL] [Abstract][Full Text] [Related]
6. Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
Javanmardi N; Fransson S; Djos A; Sjöberg RM; Nilsson S; Truvé K; Kogner P; Martinsson T
Sci Rep; 2019 Feb; 9(1):2199. PubMed ID: 30778092
[TBL] [Abstract][Full Text] [Related]
7. ALK amplification and protein expression predict inferior prognosis in neuroblastomas.
Wang M; Zhou C; Sun Q; Cai R; Li Y; Wang D; Gong L
Exp Mol Pathol; 2013 Oct; 95(2):124-30. PubMed ID: 23797004
[TBL] [Abstract][Full Text] [Related]
8. Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma.
Duffy DJ; Krstic A; Halasz M; Schwarzl T; Fey D; Iljin K; Mehta JP; Killick K; Whilde J; Turriziani B; Haapa-Paananen S; Fey V; Fischer M; Westermann F; Henrich KO; Bannert S; Higgins DG; Kolch W
Oncotarget; 2015 Dec; 6(41):43182-201. PubMed ID: 26673823
[TBL] [Abstract][Full Text] [Related]
9. Tiam1 regulates proliferation, invasion, and differentiation in neuroblastoma through the Tiam1/Rac1 signaling pathway.
Li X; Liu B; Wang X; Zhuang Y; Gao T; Sun N
Neoplasma; 2024 Feb; 71(1):37-47. PubMed ID: 38506031
[TBL] [Abstract][Full Text] [Related]
10. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
11. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
12. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
14. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
15. Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.
Fransson S; Hansson M; Ruuth K; Djos A; Berbegall A; Javanmardi N; Abrahamsson J; Palmer RH; Noguera R; Hallberg B; Kogner P; Martinsson T
Genes Chromosomes Cancer; 2015 Feb; 54(2):99-109. PubMed ID: 25251827
[TBL] [Abstract][Full Text] [Related]
16. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
17. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
[TBL] [Abstract][Full Text] [Related]
18. Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.
Liu PY; Erriquez D; Marshall GM; Tee AE; Polly P; Wong M; Liu B; Bell JL; Zhang XD; Milazzo G; Cheung BB; Fox A; Swarbrick A; Hüttelmaier S; Kavallaris M; Perini G; Mattick JS; Dinger ME; Liu T
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906397
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma.
Bordow SB; Norris MD; Haber PS; Marshall GM; Haber M
J Clin Oncol; 1998 Oct; 16(10):3286-94. PubMed ID: 9779703
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
